The Impact of Comorbidity on Patient-Reported Outcomes in Psoriatic Arthritis: A Systematic Literature Review

• Published in: Rheumatology and therapy. Vol. 7; no. 2; pp. 237 - 257
• Main Authors: Cañete, Juan D., Tasende, Jose Antonio Pinto, Laserna, Francisco José Rebollo, Castro, Susana Gómez, Queiro, Rubén
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01-06-2020; Springer Nature B.V; Adis, Springer Healthcare
• Subjects: Clinical outcomes; Comorbidity; Family Medicine; Fatigue; General Practice; Internal Medicine; Literature reviews; Medicine; Medicine & Public Health; Orthopedics; Patient-reported outcomes; Patients; Psoriatic arthritis; Quality of life; Quality of Life Research; Review; Rheumatology; Systematic literature review; Systematic review; Patient-reported outcomes; Comorbidity; Psoriatic arthritis; Systematic literature review
• ISSN: 2198-6576; 2198-6584
• DOI: 10.1007/s40744-020-00202-x

Introduction
A systematic literature review was conducted with the aim to analyse the impact of comorbidity on patient-reported outcomes (PROs) in patients with psoriatic arthritis (PsA).
Methods
A sensitive search strategy of the Medline, Embase and the Cochrane Library (up to March 2019) was applied to retrieve studies for inclusion in this systematic literature review. Abstracts of the ACR and EULAR scientific meetings were also searched. The selection criteria were: (1) patients with PsA (population) with a comorbidity (intervention) and (2) report of any impact of the comorbidity on PROs. Systematic literature reviews, randomized controlled trials and observational were included in this systematic literature review. Two of the authors selected the articles and collected the data.
Results
Eighteen articles were included in this systematic literature review, with most being cross-sectional studies that included more than 9000 patients with PsA. Some studies analysed the impact of an individual comorbidity, such as fibromyalgia (FM), and in others the analysis was according to the number of comorbidities. The most frequently analysed PROs were function, quality of life and fatigue. Analysis of the studies included in the review showed that patients with a higher number of comorbidities and/or more severe comorbidities reported worse impacts of their disease on function, patient’s global assessment (PGA), pain, fatigue, work disability and quality of life. Specifically, FM had a negative impact on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), function, quality of sleep and quality of life; anxiety and depression had a negative impact on function and fatigue; metabolic syndrome had a negative impact on BASDAI, function, PGA and quality of life; obesity had a negative impact on function and pain; smoking (current and ex-smokers) had a negative impact on pain, function, fatigue, quality of life and overall health; alcohol intake had a negative impact on pain, function, fatigue, quality of life and overall health.
Conclusions
The prevalence and impact of medical comorbidity on PROs are very high in patients with PsA.